Study of AT-752 in Healthy Subjects in a Dengue Human Challenge Model

A Phase 1, Double-blind, Randomized, Placebo-controlled Study to Assess the Antiviral Activity and Safety of AT-752 in a Dengue Human Challenge Model

Status

Terminated

Phases

Phase 1

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT05366439

Enrollment

Registered

2022-05-09

Start date

2022-04-22

Completion date

2023-03-16

Last updated

2023-04-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Dengue

Brief summary

This study will assess the safety and antiviral activity of AT-752 in healthy subjects in a Dengue Human Challenge Model

Detailed description

A Phase 1, double-blind, randomized, placebo-controlled study to assess the antiviral activity and safety of AT-752 in a Dengue Human Challenge Model

Interventions

DRUGAT-752

Parallel Assignment

DRUGPlacebo Comparator

Parallel Assignment

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Masking

TRIPLE (Subject, Caregiver, Investigator)

Eligibility

Sex/Gender

ALL

Age

18 Years to 55 Years

Healthy volunteers

Yes

Inclusion criteria

* Must agree to use protocol-specified methods of contraception * Negative pregnancy test * Willing to comply with the study requirements and to provide written informed consent

Exclusion criteria

* Pregnant or breastfeeding * Abuse of drugs * Other clinically significant medical conditions

Design outcomes

Primary

Measure	Time frame
Mean quantitative RNAemia (peak and duration and area under the plasma concentration versus time curve [AUC])	Day 2 until 28 days post virus inoculation

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026